Heron Therapeutics Inc. priced a public offering of 6 million shares at $26 apiece, hoping to raise $156 million.
Jefferies, Cowen and Evercore ISI are acting as joint book-running managers of the offering, which is expected to close by April 3.
Cantor and JMP Securities are acting as lead managers for the offering.
LifeSci Capital, Lake Street Capital Markets, National Securities Corp., Noble Capital Markets and Northland Capital Markets are each acting as co-managers for the offering.
The underwriters can purchase up to an additional 900,000 shares.
The San Diego-based biotechnology company intends to use the net proceeds for the commercial launch of HTX-011 as a treatment of post-surgery pain in the U.S. once approved.
Heron also plans to use the net proceeds for the continued commercialization of medicines Cinvanti and Sustol, which are used to prevent acute and delayed chemotherapy-induced nausea and vomiting.